Fig. 1

Human breast and pancreatic cancers reduce dendritic cell progenitors and CD141⁺ cDC1s. a Representative flow cytometry gating strategy for human BM pre-DCs, CD141⁺ cDC1s, and CD1c⁺ cDC2s, including representative final plots from a BC patient and from a healthy control. b Frequency of BM MDPs, CDPs, pre-DCs, CD141⁺ cDC1s, CD1c⁺ cDC2s, and immature granulocytes (CD11b⁺CD33^HighCD14^-CD15⁺) in baseline BC and PDAC patients relative to healthy controls. Data from BC cohort 1 and PDAC cohort 1. Healthy controls n = 12; BC n = 10; PDAC n = 19. c Frequency of circulating blood pre-DCs and immature granulocytes in baseline BC and PDAC patients relative to healthy controls. Data are from BC cohort 1 and PDAC cohort 1. Healthy controls n = 12; BC n = 10; PDAC n = 17. d Frequency of BM CD141⁺ cDC1s and granulocytes (CD45⁺CD11b⁺CSF1R⁻CD15⁺CD14⁻), and the ratio of cDC1s/granulocytes in BC patients prior to treatment or surgical intervention comparing those who achieved pathological complete response relative to patients who did not achieve pathological complete response in BC cohort 2; n = 18. Additional cohorts illustrated in Supplementary Figure 1. Error bars represent mean +/− s.e.m. or box plot; *p < 0.05, **p < 0.01, ***p < 0.001, n.s., not significant by unpaired two-sided Student’s t test